FORMAS CRISTALINAS GLYT1
La presente invencion se refiere a cuatro formas cristalinas distintas y a una forma amorfa de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il] - [5-metanosulfonil-2-( (S) -2,2,2,-trifluor-1-metil-etoxi) -fenil] -metanona y a su utilizacion para la fabricacion de composiciones farmaceuti...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | spa |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | La presente invencion se refiere a cuatro formas cristalinas distintas y a una forma amorfa de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il] - [5-metanosulfonil-2-( (S) -2,2,2,-trifluor-1-metil-etoxi) -fenil] -metanona y a su utilizacion para la fabricacion de composiciones farmaceuticas.
The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease. |
---|